The *3'UTR VNTR SLC6A3* genetic variant and Major Depressive Disorder: A systematic review

Bruna Rodrigues Gontijo[1], Isabella Possatti[1], Caroline Ferreira Fratelli[1], Alexandre Sampaio Rodrigues Pereira[1], Larissa Sousa Silva Bonasser[2], Calliandra Maria de Souza Silva[1] and Izabel Cristina Rodrigues da Silva[1,*]

[1] Graduate Program in Health Sciences and Technologies, Faculty of Ceilandia, University of Brasilia, Federal District, Brasilia 72220-900, Brazil; brunargontijo.unb@gmail.com (B.R.G.); isabellapossatti@gmail.com (I.P.); carolfratelli@gmail.com (C.F.F.); prof.alexandresampaio@gmail.com (A.S.R.P.); cdssilva@gmail.com (C.M.d.S.S.)

[2] Graduate Program in Health Sciences, University of Brasilia, Federal District, Brasilia 70910-900, Brazil; laribonasser@gmail.com

*   Correspondence: belbiomedica@gmail.com; Tel.: +55-(61)-3107-8400

Supplementary Material

Table S1. The systematic review selected articles' quality assessment according to the Genetic Risk Prediction Studies (GRIPS) guideline.

Table S1. The systematic review selected articles' quality assessment according to the Genetic Risk Prediction Studies (GRIPS) guideline.

Section/Topic		Frisch et al. [18]	Kirchheine, J., et al. [**19**]	Lavretsky et al. [20]	Huang, Chang-Chih et al. [21]	Rafikova E. I. et al. [22]	Rafikova, E.I., et al. [14]
Methods							
Study desing and Setting	4) Present key elements of study design early in the paper and Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection		x	x	x	x	x
Participants	5) Describe eligibility criteria for participants, and sources and methods of selection of participants	x	x	x	x	x	x
Variables: Definition	6) Clearly define all participant characteristics, risk factors and outcomes. Clearly define genetic variants using a widely-used nomenclature system	x	x	x	x	x	x
Variables: Assessment	7) (a) Describe sources of data and details of methods of assessment (measurement) for each variable.		x	x		x	x
	(b) Give a detailed description of genotyping and other laboratory methods.	x	x	x	x	x	x
	8) (a) Describe how genetic variants were handled in the analyses	x	x		x	x	x
Variables: Coding	(b) Explain how other quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why.	x	x	x	x	x	x

Analysis: Risk model construction	9) Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables were initially examined or considered for inclusion in models. Include details of any variable selection procedures and other model-building issues. Specify the horizon of risk prediction (e.g., 5-year risk).	x	x	x	x	x	X
Analysis: Validation	10) Specify the procedure and data used for the validation of the risk model.		x	x	x	x	x
Analysis: Missing data	11) Specify how missing data were handled		x				
Analysis: Statistical methods	12) Specify all measures used for the evaluation of the risk model including, but not limited to, measures of model fit and predictive ability		x	x	x	x	x
Analysis: Other	13) Describe all subgroups, interactions, and exploratory analyses that were examined	x	x	x	x	x	x

X - present

Table S1. *Cont.*

Section/Topic		Frisch et al. [18]	Kirchheine, J., et al. [19]	Lavretsky et al. [20]	Huang, Chang-Chih et al. [21]	Rafikova E. I. et al. [22]	Rafikova, E.I., et al. [14]
Results							
Participants	14) Report the numbers of individuals at each stage of the study. Give reasons for nonparticipation at each stage. Report the number of participants not genotyped, and reasons why they were not genotyped.		x	x		x	x
Descriptives: Population	15) Report demographic and clinical characteristics of the study population, including risk factors used in the risk modeling.	x	x	x	x	x	
Variables: Definition	16) Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted estimates and their precision from the full risk model(s) for each variable.	x	x	x	x	x	x
Descriptives: Model estimates	17) Descriptives: Model estimates	x	x	x	x	x	x
Assessment	18) Report measures of model fit and predictive ability, and any other performance measures, if pertinent.		x	x	x	x	x
Validation	19) Report any validation of the risk model(s)	x	x	x	x	x	X
Other analyses	20) Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent	x	x	x	x	x	X

Discussion								
Limitations	21) Discuss limitations and assumptions of the study, particularly those concerning study design, selection of participants, and measurements and analyses, and discuss their impact on the results of the study	x	x	x	x	x	x
Interpretation	22) Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	x	x	x	x	X	x
Generalizability	23) Discuss the generalizability and, if pertinent, the health care relevance of the study results	x	x		x	x	x

X - present